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Background: Lower back pain is one of the most common health-related complaints in the 
adult population. Thirty percent of Americans 65 years and older reported symptoms of lower 
back pain in 2004 (NCHS, 2006). Injection treatment is a commonly used non-surgical procedure 
to alleviate lower back pain in older adults. However, the effectiveness of injection treatment, 
particularly in older adults, has not been well documented.
Objective: This study quantified the effectiveness of injection treatment on pain relief among 
adults 60 years and over who were diagnosed with degenerative lumbar spinal stenosis, a common 
cause of lower back pain in older adults. The variations of the effectiveness were examined by 
selected patient attributes. 
Study Design: Prospective, non-randomized, observational human study.
Setting: Single institution spine clinic.
Methods: Patients scheduled for lumbar injection treatment between January 1 and July 1, 
2008 were prospectively selected from the study spine clinic. Selection criteria included patients 
age 60 and over, diagnosed with degenerative lumbar spinal stenosis and no previous lumbar 
injection within 6 months or lumbar surgery within 2 years. The pain sub-score of the SF-36 
questionnaire was used to measure pain at baseline and at one and 3 months post injection. 
Variations in longitudinal changes in pain scores by patient characteristics were analyzed in both 
unadjusted (univariate) analyses using one-way analysis of variance (ANOVA), and adjusted 
(multiple regression) analyses using linear mixed effects models.
Limitations: This study is limited by its sample size and observational design.
Results: Of 62 patients receiving epidural steroid injections, the mean Pain score at baseline 
was 27.4 (SD =1 3.6), 41.7 (SD = 22.0) at one month and 35.8 (SD = 19.0) at 3 months. Mean 
Pain scores improved significantly from baseline to one month (14.1 points), and from baseline 
to 3 months (8.3 points). Post injection changes in pain scores varied by body mass index (BMI) 
and baseline emotional health. Based on a linear mixed effects model analysis, higher baseline 
emotional health, as measured by the SF-36 Mental Component Score (MCS≥50), was associated 
with greater reduction in pain over 3 months when compared to lower emotional health (MCS 
<50). In patients with higher emotional health, pain scores improved by 14.1 (P < .05: 95% CI 
6.9, 21.3). Patients who were obese also showed significant improvement in pain scores over 3 
months compared to non-obese patients. In obese patients, pain scores increased by 7.9 (P <.05; 
95% CI:1.0, 14.8) points.
Conclusion: Lower back pain in older adults with degenerative lumbar spinal stenosis might be 
clinically significantly alleviated after injection treatment. Pain relief varies by a patient’s personal 
and clinical characteristics. Healthier emotional status and obesity appears to be associated with 
more pain relief experienced over 3 months following injection.
Key words: Degenerative lumbar spinal stenosis, low back pain, older adults, epidural steroid 
injection, MRI, SF-36, Pain sub-score.
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functional improvement with injection (e.g., severe Par-
kinson disease, or hemiparesis) or amputation of any 
lower extremity. All patients who agreed to participate 
provided signed consent forms and completed one 
general health questionnaire and one questionnaire 
specific to back pain before their scheduled injections. 
Eighty-nine patients were approached to participate in 
the study and 86 (96%) agreed and completed baseline 
questionnaires.
Approximately 3 weeks following baseline injec-
tion, participants were mailed one-month follow-up 
questionnaires. If the questionnaires were not returned 
within 2 weeks, the participants were contacted by 
phone. Two additional calls were made if the surveys 
were still not returned. The process was repeated for 
the 3-month follow-up period (Fig. 1).
Epidural Steroid Injection Procedure
Patients of 2 physiatrists were included in the 
study. One physiatrist administered injections to 93.5% 
of patients (n = 58). In the procedure room, the pa-
tient was placed in a prone position. The skin over 
the intended interlaminar target site was marked and 
prepped in the usual sterile fashion. The skin and sub-
cutaneous tissue were anesthetized with 1% lidocaine 
mixed with sodium bicarbonate 8.4% (10:1). The tip of 
a 20-gauge, 3.5-inch Tuohy spinal needle was advanced 
under intermittent fluoroscopic guidance toward the 
target. Loss of resistance with air was used to identify 
the epidural space. After negative aspiration for blood 
and cerebrospinal fluid, Isovue (Bracco Diagnostics, Pri-
neton, NJ) was injected to confirm epidural placement. 
Subsequently, 5 mL of injectate (1 mL triamcinolone 
acetonide [40 mg/mL] and 4 mL 0.5% preservative-free 
Xylocaine [AstraZeneca, Wilmington, DE]) was admin-
istered. The needle was removed. For multiple levels, 5 
mL of injectate was distributed equally between levels 
injected. For caudal injections, 10mL of injectate (1 mL 
triamcinolone acetonide [40 mg/mL], 5 mL preservative-
free normal saline, and 4 mL preservative-free 0.5% Xy-
locaine) was slowly administered without resistance.
Outcome Measure
The primary outcome measure used for this study 
was the paper and pencil version of the Short Form-
36 (SF-36 version 2) (14). The SF-36 Questionnaire is a 
multi-purpose 36-item questionnaire used to assess 
functional health and well-being of adults. It is one 
of the most frequently used questionnaires to assess 
health related quality of life in patients with back pain 
Lower back pain is one of the most common health-related complaints in the adult population. Thirty percent of Americans 65 years and older 
reported symptoms of lower back pain in 2004 (1). With 
an aging population, the proportion of people over the 
age of 65 is expected to reach 20% by the year 2030. 
Because of this increase in older adults, lumbar spinal 
stenosis (LSS) associated with arthritic changes will also 
likely increase. In older adults, lower back pain is most 
often caused by degenerative lumbar spinal stenosis. 
Stenosis is the narrowing of the spinal canal, causing 
pressure on the nerve roots, and is frequently treated 
surgically. LSS is one of the most common reasons for 
back surgery in patients 65 years and older (2). However, 
risks associated with surgery increase with age (3-5) and 
older patients might choose non-surgical treatment for 
their lower back pain, including injection treatment. 
Injection treatment, usually consisting of anti-in-
flammatory medications and analgesics, has improved 
since the mid 1990s when fluoroscopic guidance was 
developed (6). Information about injection treatment 
for lower back pain is limited, especially in the older 
population. An extensive review of published litera-
ture regarding injection treatment revealed a paucity 
of information about older adults diagnosed with de-
generative LSS (6-13). In this study, pain relief follow-
ing injection treatment has been examined in patients 
over age 60, diagnosed with degenerative LSS primarily 
caused by degenerative changes. Variations in pain re-
lief according to patient attributes were also assessed. 
To our knowledge, such results have not been reported 
in the literature.
Methods
Participants
All patients ≥ 60 years old, who had been diagnosed 
with degenerative LSS and were scheduled to receive 
any lumbar injection for lower back pain at a single in-
stitution spine clinic were eligible for review. Diagnosis 
of LSS was confirmed using magnetic resonance imag-
ing (MRI) reports and clinical notes. Potential study par-
ticipants were identified by reviewing injection room 
schedules 2 weeks in advance. Exclusion criteria were re-
ceipt of a previous injection in the lumbar region within 
the past 6 months; lumbar surgery within the past 2 
years; history of lumbar fracture; acute disc herniation; 
malignancy or infection; inability to provide informed 
consent due to dementia or cognitive impairment; co-
existing musculoskeletal conditions that would negate 
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(15) and has been used in large-scale studies examining 
musculoskeletal issues, including a prospective study by 
Zanoli (15) examining 451 patients with degenerative 
lumbar spine disorders. The SF-36 was also used by Vogt 
et al (16), in the evaluation of 5,995 men 65 years and 
older in the Osteoporotic Fractures in Men Study. 
The questionnaire represents multiple indicators of 
health including 8 components. Four of these compo-
nents relate to physical health and produce the mea-
sure Physical Component Summary (PCS). The remain-
ing 4 components relate to mental health and produce 
the Mental Component Summary (MCS). In this study, 2 
components were used; the Pain sub-score of the PCS 
(as a primary outcome for long-term pain) and the MCS 
(as a covariate).
The SF-36 surveys were scored using QualityMetric 
SF-36 scoring software (QualityMetric, Inc., Lincoln, RI) 
by a research assistant. Training to use the scoring soft-
ware was given by the orthopedics department research 
coordinator. All survey scores were manually entered 
into an ACCESS database form by the research assistant 
and every fifth record was checked for accuracy by the 
primary investigator. 
Covariates
To assess physical attributes that could affect the 
response to treatment for pain and function, informa-
tion about gender, age, body mass index (BMI), hip or 
knee replacement surgery history and co-morbidities 
was collected. Co-morbidities were scored using the 
Charlson Comorbidity Index (CCI) (17). The CCI includes 
19 co-morbidities, selected based on their association 
with mortality. It includes conditions related to can-
cer, diabetes, heart disease, liver disease, renal disease, 
chronic pulmonary disease and others. Following re-
trieval of diagnostic histories using electronic medical 
files, medical conditions relevant to the Charlson Index 
were recorded and the Index was computed by the first 
author. Results were verified by a dedicated orthope-
dic research resident. Medical records were also used to 
collect information on patient history of hip or knee re-
placement surgery to adjust for other lower extremity 
arthritic changes common in this age group and were 
included in the analysis.
MRI reports were reviewed for information about 
LSS diagnosis. Reports that indicated acute disc hernia-
tion in the lumbar region as being the primary diag-
Fig. 1. Patient enrollment
 
 
 
 
 
 
 
 
 
 
 
 
86 patients enrolled and completed 
baseline surveys 
(January 1, 2008 – July 1, 2008) 
4 withdrew from the study 
1 received 2nd injection before 1 month 
1 never received baseline injection 
4 did not return one-month surveys 
7 received nerve blocks 
6 received radiofrequency denervation 
1 died 
62 patients still enrolled 
62 returned SF-36 one-month surveys 
1 month follow-up 
3 months follow-up 1 withdrew from the study 
4 did not return three-month surveys 
 
61 patients still enrolled 
56 returned three-month surveys 
 
Pain Physician: November/December 2010; 13:E347-E355
E350  www.painphysicianjournal.com
noses were not included in the study. When available, 
images were reviewed to determine LSS severity. A mid 
sagittal diameter of ≥ 13 mm was classified as “mild,” 
11mm to 12 mm was classified as “moderate” and ≤ 11 
mm was classified as “severe” (18,19). 
To adjust for other pain control medications that 
might interfere with injection treatment, information 
about narcotic use was also collected. Medication lists 
were reviewed using electronic records and noted as 
“yes” or “no” regardless of dosage or medications. Nar-
cotic use was defined as being used or reported within 
three months of baseline injection.
To adjust for other lower extremity joint arthritis 
common in this age group, information was collected 
on history of total hip or knee replacement surgery us-
ing medical records. Demographic and anthropometric 
information was collected using hospital administrative 
data and medical records. Information was also col-
lected on body mass index (BMI) and demographic vari-
ables (gender, age and race). Information about race 
was not consistently reported in patient files and was 
not included in the analysis.
Data Collection
Demographic information was collected using hos-
pital administrative data and medical records. Survey 
scoring was accomplished using Quality Metrics scoring 
software for the SF-36 survey. A standard form was cre-
ated and a corresponding data management program 
was developed using Microsoft ACCESS (20). Data col-
lected on paper forms were entered by a trained re-
search assistant and the first author. Quality of data 
entry was verified by reviewing every fifth record. AC-
CESS files were then exported using StataTransfer. All 
statistical analyses were completed using Intercooled 
STATA 9.0 (21).
Statistical Analysis
Descriptive statistics summarize patient character-
istics such as gender, baseline emotional status (MCS), 
BMI, co-morbidities, narcotic use and history of total 
hip or knee replacement surgery (THKR) (Table 1). 
Baseline MCS and BMI were transformed to categori-
cal variables. For categorical variables (gender, base-
line MCS, BMI, co-morbidities, narcotics and THKR), 
numbers and percentages were presented. Age was 
presented as a continuous variable with mean, stan-
dard deviation and range. T-tests compared physical 
function between baseline and one month and be-
tween baseline and 3 months for each patient charac-
teristic category (i.e. gender, age 60-69, age 70+, etc.) 
(Table 2). Differences in pain score changes among pa-
tient categories (i.e. BMI groups) were assessed using 
analysis of variance tests. Significant variables in the 
univariate analysis were entered into a multiple re-
gression model. Change in pain was examined in a se-
ries of linear mixed effects models. The mixed effects 
model assumes that repeated measurements in the 
same individual are not independent and allows indi-
viduals to have unequal numbers of observations. In 
this study, the outcome measure included function at 
baseline, one month and 3 months and the covariates 
Table 1. Patient characteristics at baseline
Characteristic N %
SF-36 Pain Score 
Baseline
Mean (SD)
Total 65 100 27.4 (1.7)
Age
       Mean 74 - -
       SD 8.1 - -
       Range 60-90 - -
Gender
    Male 21 32 28.8 (14.2)
    Female 44 68 26.7 (13.3)
SF-36/MCS  *
    Low (< 50) 26 40 21.3 (10.5)
    High (≥50) 39 60 31.4 (13.9)
Body Mass Index
    Normal Weight (<25) 14 21 28.5 (13.2)
    Overweight (25-29.9) 17 26 26.4 (14.0)
    Obese (30-34.9) 12 18 30.8 (16.4)
    Morbidly Obese (≥35) 12 18 27.6 (7.7)
Comorbidities  *
    0 31 48 28.0 (14.7)
    1 10 15 22.3 (12.3)
    2 11 17 30.7 (13.4)
    ≥3 13 20 26.9 (11.9)
Narcotic Use  *
    Yes 16 25 22.1 (12.6)
    No 38 58 29.4 (14.1)
Hip or Knee Replacement
    Yes 11 17 30.2 (15.8)
    No 43 66 26.5 (13.6)
Note: Mean SF-36 Pain score for the general population = 75.2 
(SD=23.7) (22)
Baseline scores between group categories compared: *  P <.05 (t-test); 
** P <.05 (chi-square)
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included MCS, BMI, gender, age and co-morbidities. 
The outcome measure was collected at 3 timepoints, 
and some of both outcome data and covariate infor-
mation were missing. The fixed effects portion of the 
model consisted of the variables that were significant 
in the univariate analysis (analysis of variance). Patient 
level intercepts were modeled as random effects. This 
term accounts for between-subject variation. For ex-
ample, in this study, baseline measurements of pain 
were analyzed as separate values for each patient, 
rather than as a mean. Unconditional models (fixed 
time) and conditional models (fixed time, BMI, MCS, 
age, gender) were compared to determine changes in 
variance after the addition of variables to the mod-
el. Akaike’s information criterion was used to assess 
goodness-of-fit between the models.
All variables in the analysis were also tested for 
an interaction with time (age, gender, baseline emo-
tional health, BMI, co-morbidities, narcotic use, hip or 
knee replacement). Likelihood ratio tests were used to 
compare models with and without time/variable inter-
actions. Test results producing significant P-values (P < 
.05) indicated time interactions were present and were 
included in the final model. By adding variables into 
Table 2.  Change in SF-36 Pain scores from baseline to one month and baseline to three months.
Patient characteristics
SF-36 Pain change
Baseline  to 1 month
 mean (SD) N=61
p
SF-36 Pain change
Baseline  to 3 months 
 mean (SD) N=56
p 
Total (n) 14.1 (9.5, 18.7) <.05 8.3 (4.0, 12.6) <.05
Gender
    Male 10.9 (2.7, 19.0) <.05 9.4 (4.0, 14.7) <.05
    Female 15.4 (9.7, 21.1) <.05 7.7 (1.8, 13.7) <.05
Age
    60-70 16.2 (7.7, 24.7) <.05 7.6 (-0.12, 15.3) <.05
    >70 12.8 (7.2, 18.3) <.05 8.7 (3.4, 14.0) <.05
Emotional Status  (SF-36/MCS) **
    < 50 9.5 (3.9, 15.0) <.05 8.1 (3.5, 12.7) <.05
    ≥ 50 17.3 (10.5, 24.1) <.05 8.4 (2.0, 14.8) <.05
Body Mass Index *
    Normal Weight (<25) 15.3 (7.6, 23.0) <.05 3.9 (-6.6, 14.4) 0.44
    Overweight (25-29.9) 1.4 (-5.3, 8.2) 0.66 6.7 (-0.68, 14.1) 0.07
    Obese (30-34.9) 19.6 (7.1, 32.1) <.05 7.9 (-5.2, 21.0) 0.21
    Morbidly Obese ( ≥35) 19.9 (1.32, 38.5) <.05 14.8 (7.0, 22.5) <.05
Narcotics
    Yes 14.8 (5.9, 23.7) <.05 10.7 (3.6, 17.7) <.05
    No 13.2 (7.4, 18.9) <.05 6.7 (0.43, 13.0) <.05
Co-morbidities      *
    0 10.9 (5.3, 16.5) <.05 7.0 (1.3, 12.7) <.05
    1 18.2 (3.7, 32.7) <.05 17.9 (6.4, 29.4) <.05
    2 15.5 (2.4, 28.6) <.05 -1.2 (-12.9, 10.5) 0.82
    ≥3 17.2(2.8, 31.5) <.05 11.2 (0.23, 22.1) <.05
Hip or Knee Replacement
    Yes 11.0 (-4.9, 26.8) 0.16 3.9 (-6.8, 14.5) 0.43
    No 14.4 (9.8, 19.0) <.05 9.1 (3.6, 14.5) <.05
P-values represent t-test results comparing baseline and follow-up scores;
1 month change in pain = 1 month SF-36 Pain - baseline SF-36 Pain; 
3 months change in pain = 3 months SF-36 Pain - baseline SF-36 Pain;
* One way ANOVA P-values ≤ .05; **One way ANOVA P-values ≤ .10. Compared variable categories (i.e. male v. female)
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the model individually, potential interactions between 
variables were also evaluated and significant interac-
tions were included in the final model. Model assump-
tions of linearity, normality, independence of errors, 
and homoscedasticity of errors were examined graphi-
cally and analytically and were adequately met. ACCESS 
files were exported using StatTransfer 9 for statistical 
analyses using Intercooled STATA 9.0. All available data 
from all participants were used, as long as at least one 
follow-up survey was returned. 
Results
Eighty-six patients were initially enrolled and com-
pleted baseline SF-36 questionnaires administered by 
the first author from January 1, 2008 to July 1, 2008. 
All patients signed study consent forms approved by 
the Internal Review Board. Participants were followed 
at one month and at 3 months following baseline in-
jection (Fig. 1). At one month, 4 participants withdrew 
from the study, 2 were dropped from the study (for 
having a second injection before follow-up (n=1) or for 
never having the first injection (n=1), 4 did not return 
the first follow-up surveys, 7 received nerve blocks, 6 
received radiofrequency denervation and one died. Of 
the initial 86 participants, 62 were still enrolled after 
one month and 62 returned SF-36 surveys. At 3 months, 
one withdrew from the study and 4 did not return the 
second follow-up surveys. At the end of the second fol-
low-up period, 61 participants were still enrolled and 
56 returned 3-month surveys. All patients remaining in 
the study received epidural steroid injections.
Participant characteristics including gender, emo-
tional status (MCS), BMI, co-morbidities, narcotic use 
and history of total hip or knee replacement surgery 
(THKR) are summarized and presented in Table 1. The 
mean age of participants was 74 (SD = 8.1, range 60 to 
90), 69% were female, 60% had high emotional health 
(MCS ≥ 50) and 36% were obese to morbidly obese (BMI 
≥ 30). Baseline scores differed significantly by patient 
characteristics including baseline emotional health and 
body mass index.
Changes in SF-36 Pain scores at one and 3 months 
were tabulated overall and by patient characteristics in 
Table 2. Overall, significant improvement was found at 
both one month and 3 months follow-up. SF-36 Pain 
scores showed a 14.1 (P < .05; 95% CI: 9.5, 18.7) point 
reduction in pain at one month and an 8.3 (P < .05; 95% 
CI:4.0, 12.6) point reduction in pain at 3 months. Sig-
nificant differences (P < .05) in pain score changes from 
baseline to one month were found between BMI and 
emotional status categories. Baseline, one month and 
3-month means of pain scores are presented in Fig. 2.
Results from a linear mixed effects model analysis 
are presented in Table 3. Variables found to have sig-
nificantly different pain score changes at either one or 
3 months were included in the analysis (BMI and MCS) 
as well as gender and age. No variable interactions or 
interactions with time were found or included. To ac-
count for small sample size, body mass index categories 
were collapsed to 2 categories, obese (BMI ≥ 30kg/m2) 
and non-obese (BMI < 30kg/m2). Comparison of cova-
riance estimates of the conditional model showed a 
modest improvement in goodness of fit (0.69%, 0.93%, 
0.79% and 0.64% of additional variance explained for 
emotional health, BMI, age and gender, respectively; 
P -value < .05) when compared to the unconditional 
model (time alone). 
The only variables showing significance were base-
line emotional health and body mass index. Pain scores 
were significantly improved for patients with high base-
line emotional health and for patients who were obese. 
In patients with high baseline emotional health, Pain 
scores improved by 14.1 (P < .05; 95%CI 6.9, 21.3) points 
over 3 months, as compared to patients with low base-
line emotional health. In patients who were obese, pain 
scores improved by 7.9 (P < .05: 95% CI; 1.0, 14.8) points 
over three months, as compared to patients who were 
non-obese. Mean pain scores at baseline, one month 
and 3 months by emotional health status and by BMI 
status are presented in Figs. 3 and 4.
Fig. 2. Mean Pain scores at baseline, one month and 3 months.
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discussion
This study provides new information about injec-
tion effectiveness in the older adult population. Despite 
the fact that degenerative LSS occurs more frequently 
in aging adults (23) and affects 5 of every 1,000 Ameri-
cans over age 50 (24), the effectiveness of injection 
treatment is understudied. This study provides much 
needed quantitative information on the effectiveness 
on pain relief of injection therapy using steroids and 
analgesics.
There were 3 main findings of this study. First, sig-
nificant pain relief was observed in older adults for up 
to 3 months after injection treatment. Second, patients 
with high emotional status experienced more pain re-
lief than patients with low emotional status. Third, pain 
relief varied by body mass index.
Body mass index has been associated with comor-
bidities, including osteoarthritis and back pain, in pre-
vious literature (25). Obesity has also been associated 
with higher fatigue and less activity, especially in pa-
tients with knee osteoarthritis (26). In this study, pa-
tients who were obese to morbidly obese experienced 
more pain relief than non-obese patients. Variations in 
response to pain treatment could be associated with 
lower activity levels in obese patients, resulting in less 
pain. The effects of injections could also have been less 
effective in patients with a history of hip or knee ar-
thritis, as noted in an earlier study by Bischoff-Ferrari 
(27). There are 2 possible explanations for this response: 
First, arthritis might be more advanced in these patients 
than in patients who have not had hip or knee surgery, 
which might have affected their response to injection 
medications. Second, referred hip and/or knee pain 
might confound pain relief due to local treatment of 
the lumbar stenosis. Inconsistent results found in these 
groups could also be due to the size of the sample, es-
pecially when distributed among sub-categories. 
Table 3. Predictors of  change in pain over 3 months (multiple 
regression)
Patient characteristics
SF-36 Pain
change
β (95%CI)
BMI (obese vs. non-obese) 7.9 (1.0, 14.8) *
MCS baseline (<50 vs. ≥50) 14.1 (6.9, 21.3) *
Age (60-69, vs. 70+) 0.25 (-6.7, 7.2)
Gender (male vs. female) -0.39 (-8.2, 7.4)
Based on linear mixed effects model analysis; * p<.05;
Fig. 3. Mean Pain scores at baseline, 1 month and 3 months 
by emotional health status.
Fig. 4. Mean pain scores at baseline, 1 month and 3 months 
by body mass index.
High emotional status was found to be strongly 
associated with greater improvement in pain at one 
month. This finding parallels findings in previous stud-
ies examining other musculoskeletal disorders, includ-
ing total knee replacement (28) and total hip replace-
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ment (27). However, this is the first study on older 
patients diagnosed with degenerative LSS to produce 
these results. It is important to note that participants 
with low emotional health had more pain at baseline 
(PCS=21.3) compared to patients with high emotional 
health (31.4). Thus, it is not clear if greater pain pre-
ceded the lower emotional health or vice versa. This 
will provide clinicians with valuable information when 
screening their patients at baseline. If emotional status 
has an impact on how well patients respond to injec-
tion treatment, clinicians may discuss this association 
with patients. This change might maximize the benefit 
of injection treatment in this sub-population of aging 
patients. 
A limitation of this study was that the effects of 
LSS severity could not be determined. Stenosis sever-
ity has been documented in previous studies using 
MRI films for measurement (13,18,19). In this study, 
only a minority of original MRI films were available 
to the study team for review and severity informa-
tion could not be consistently collected. However, 
MRI reports were available and reviewed to confirm 
diagnosis. Reports that indicated disc related LSS as 
being the primary diagnosis were not included in the 
study.  Future research projects examining injection 
treatment for degenerative LSS should determine im-
age availability before data collection begins.
A second limitation was the study size. Enrollment 
of study participants was limited to one location over a 
relatively short period of time (6 months). The inclusion 
of patients from only one study center might affect the 
generalizability of the response to treatment found in 
this cohort. However, this was the first study to examine 
the results of injection treatment in older adults with 
a diagnosis of LSS specifically caused by degenerative 
changes. In addition, the study site was a clinic specifi-
cally designed to treat patients with back pain, serving 
a diverse population in a large metropolitan city in the 
northeast. As the only spine center in the area, the pa-
tient population is representative of the surrounding 
area. These results could be used in the design of fu-
ture, multicenter studies. 
A third limitation of this study included a lack of 
sufficient power to determine the differences in treat-
ment effects within these sub-categories (BMI and 
emotional health), making it impossible to make rec-
ommendations according to specific conditions for po-
tential patients. Future research should increase sample 
size to adequately examine the relationship between 
patient characteristics and injection effectiveness, espe-
cially in regard to emotional health status as a potential 
predictor of outcome.
Study design might also be considered a limitation. 
Ideally, a comparison group would have provided the 
best information in determining injection treatment 
effectiveness in this cohort. However, a randomized 
control design poses problems with invasive procedures 
such as injection treatment. Many clinicians recommend 
injection treatment for lower back pain as a last resort 
before surgery. Randomizing patients to either surgery 
or injection treatment could likely cause some ethical 
considerations in study design.  Selection bias was also a 
potential limitation of this study. Though consideration 
of this potential problem was addressed in study de-
sign (by enrolling all patients who met study inclusion 
criteria and agreed to participate), patients who chose 
to participate might have had different characteristics 
from those who refused. However, patients who agreed 
to participate were compared to patients who did not 
agree, and had similar characteristics (age, gender).  
Additional information about other patient char-
acteristics such as socioeconomic status and lifestyle 
might have also been useful in assessing differences in 
response to injection treatment. However, in this study, 
patient surveys were completed within a short period 
of time before entering the injection room and time 
was limited. Future studies could benefit from collect-
ing this information at a less sensitive time.
In general, pain scores improved substantially one 
month after treatment. Three months after treatment, 
an improvement was seen as well, but not as strong as 
at one month. Clearly, pain medications administered 
by injection did not have a lasting effect, but were still 
providing some pain relief even after 3 months. Though 
this amount of pain relief will be satisfactory for some 
patients, others might prefer a longer effect and could 
prefer surgery to injection treatment. However, this in-
formation will be useful for clinicians who consider of-
fering injections as an option for their aging patients.
conclusion
The results of this study suggest that injection treat-
ment might reduce lower back pain in older patients 
with degenerative LSS for up to 3 months or more. 
Treatment effects might vary by patient characteristics 
which should be considered when referring patients 
to injection treatments. To further examine potential 
predictors of achieving maximum pain relief, future 
research should increase sample size. An important 
finding of this study was that good baseline emotional 
Injection for Back Pain Associated with Degenerative Lumbar Spinal Stenosis
www.painphysicianjournal.com  E355
health demonstrated a strong association with pain 
level following injection treatment. Future research 
should take this important relationship into account in 
study design.
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